Metformin-d₆ (hydrochloride)

Territorial Availability: Available through Bertin Technologies only in France

• Synonyms
  • N,N-dimethyl-d6-imidodicarbonimidic diamide, monohydrochloride
• Correlated keywords
  • 1185512-92-8 apo-metformin benofomin brot dabex denkaform dextin diabefagos aiabetmin diabetosan diabex dialon diformin retard dimefor geamet glifage glucaminol glucofago glucoform glucomet glucomin glucomine gluconil glucophage-850 forte retard glucophage-SR mite gludepatic glufor gluformin glumeformin glumetza glumin-XR glupermin glyceriphage glyciphage glycon glyformin LA6023 LA-6023 meguan metforal metomin miformin siamformet biguanide antihyperglycemic blood glucose non-insulin-dependent diabetes mellitus mitochondrial respiratory chain complex 1 AMPK gluconeogenesis cancer derivative noninsulin insulin inhibiting inhibit uptake complex 1 skeletal muscle suppress hepatic gluconeogenesis hepatic steatosis ob/ob ovarian ovary syndrome tumor agent deuterated deuterium internal quantifies quantify quantification GC-MS GC/MS gases chromatography masses spectrometry LC-MS LC/MS liquid isotope NASH non-alcoholic nonalcoholic steatohepatitis NAFLD nonalcoholic fatty liver disease
• Product Overview:
  Metformin-d6 is intended for use as an internal standard for the quantification of metformin (Item No. 13118) by GC- or LC-MS. Metformin is a biguanide with diverse biological activities.{21403,13720,43272,43273} Metformin (250 mg/kg, i.p.) increases hepatic AMPK activity and reduces blood glucose by more than 50% in a liver kinase B1-dependent manner in mice fed normal and high-fat diets, respectively, and reduces blood glucose by 40% in ob/ob mice.{13720} It reduces weight gain, hepatic lipid droplet content, and total cholesterol, LDL cholesterol, and triglyceride levels in the plasma of diet-induced obese mice when administered at doses of 10 or 50 mg/kg per day.{43273} It also reverses increased hepatic triglyceride and apolipoprotein A5 levels, as well as hepatic steatosis, in a dose-dependent manner in an ob/ob mouse model of non-alcoholic fatty liver disease (NAFLD).{43274} Metformin (250 mg/kg) reduces tumor growth in an HCT116 p53– human colon cancer mouse xenograft model, but has no effect on HCT116 p53– tumors overexpressing recombinant S. cerevisiae Ndi1 NADH dehydrogenase, a single-subunit ortholog of the multi-subunit mammalian mitochondrial complex I.{43272} Formulations containing metformin have been used in the treatment of type 2 diabetes.